drugset / Trial / NCT03414541

Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease

NCT03414541 ↗

Phase 2 Completed 49 enrolled Afimmune
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered DS102 capsules versus placebo in the treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start
2017-09-24
Primary completion
2019-01-11
Completion
2019-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject DS102 Unknown 500 mg Oral
Subject DS102 Unknown 1000 mg Oral